The consumer price index report released by the Department of Labor on Wednesday showed prescription drug prices fell 1.2 percent in September and were down 4.5 percent from a year earlier. The government labeled this the smallest annual change ever recorded, meaning the largest annual decline on record. The 3.1 percent annual drop in July was the steepest since March 1963, when prices fell 3.2 percent, but September’s figures went beyond that. The article calls this a substantial development for a country where expensive medicine has long seemed permanent.
Summary written by Upside AI from the original article. Read the source for full details.
Read the original on hotair.com ↗
Related news
- US delays small imports rule that raised alarm over prescription drug costs
- Rocket Lab Just Booked Its Biggest Contract Ever (Again)
Rocket Lab received an order from Japanese customer Synspective for 20 more Electron launches, announced September 30, bringing Synspective's total to 47 launches and making it Rocket Lab's largest customer. The company calls this its largest-ever Electron deal, excluding the 20 HASTE launches. Rocket Lab did not disclose pricing, but at its most recently advertised price of $8.4 million per launch, the 20 launches would generate about $168 million between 2028 and 2031. The deal pushes the company's backlog beyond 100 missions, or more than $840 million in future revenue. The article notes that Neutron's first launch has been postponed to 2027, and argues Rocket Lab could turn profitable in 2027 thanks to the pending Iridium purchase, with or without Neutron.
- This Drug Combination for Eli Lilly Generated Significantly More Weight Loss Than Just Zepbound, but Discontinuation Rates Were Also Far Higher. Here's What This Could Mean for the Stock
Eli Lilly tested tirzepatide (the active ingredient in Zepbound) combined with eloralintide, an experimental drug targeting the amylin hormone rather than GLP-1. After 48 weeks, the combination produced weight loss of up to 23.3%, versus 14.8% with tirzepatide alone and 12.3% with eloralintide alone. However, discontinuation rates due to side effects reached as high as 27%, though Lilly’s Ken Custer noted that high discontinuation was also seen with tirzepatide in a mid-stage trial and that dosing can matter. The author views the results as a net positive but flags a steep valuation, with a market cap above $1 trillion and the stock trading near 40 times trailing earnings after rising around 10% this year.
- Google Says It Just Cracked One of Quantum Computing's Biggest Bottlenecks
Google Quantum AI reported in a Science paper that the magic state cultivation technique cut errors about 40-fold on its Willow chip, producing magic states with 99.99% fidelity. Magic states are single-use resources needed for useful quantum programs, and some estimates put their creation cost at up to 95% of a quantum computer's capacity. Rather than requiring a dedicated factory, the technique works like a filter on a small patch of the chip, with only about 8% of attempts passing every check. It is one of the methods behind Gidney's 2025 estimate that RSA-2048 encryption could be broken with under a million noisy qubits. The experiment used at most 54 of Willow's 105 qubits, while factoring RSA-2048 would require magic states with errors around one in 10 billion.
- Microsoft Just Took Its Biggest Step Toward Independence From Nvidia
Microsoft announced Azure Maia 300, its newest in-house AI chip, and said Maia will become the primary inference system for its products, with multi-gigawatt deployments starting in 2027. Microsoft claims Maia 300 produces 40% more tokens per megawatt than leading GPU systems, though its 96-chip rack draws about 167 kilowatts versus 142 kilowatts for Nvidia's 72-GPU GB300 rack. The chip is meant to lower the cost of Microsoft's own Copilot and OpenAI services, which it does not sell as chips, while the company expects capital spending above $175 billion this calendar year and will keep leasing Nvidia chips for training. Evercore ISI estimates Maia will account for about 10% of Microsoft's AI chip spending by early 2027. All performance figures come from Microsoft and have not been tested independently, and the next checkpoint is the October 28 earnings call.
Related markets
Latest news
- Iran warns US and Israel
Iran's Armed Forces Chief of Staff, Major General Ali Abdollahi, warned on October 18 that the US and Israel would face a far harsher response if they continue actions Tehran considers provocative. He said Tehran is awaiting their next moves and that Iran's armed forces remain ready for any scenario. Tehran accuses Washington and Tel Aviv of trying to weaken its government, and tensions have risen since earlier conflicts, including a 12-day war. Iran says it will not back down under external pressure.
- Is TC Energy (TRP) a Good or Bad Investment at Today's Multiple?
TC Energy trades at 21.19 times next year's expected earnings, closing at $61.74 on October 16 after a 1.5% return over 6 months, versus 10.5% for the Insider Monkey Billionaire Index and 9.3% for the State Street SPDR S&P 500 ETF Trust. The company operates natural gas transmission pipelines across Canada, the United States and Mexico, plus power generation, with a 44.25% operating margin, and latest-quarter earnings rose 18.00% on revenue up 5.70%. The article flags risks including debt at 170.37% of equity, the loss of crude oil pipelines to South Bow in 2024, and volumes that depend on North American gas demand from power and LNG exports. A 4.01% yield is cited as income while the market decides whether the stable business justifies the multiple relative to its growth.
- Should You Buy This Trump AI Stock Ahead of Earnings?
Microsoft (MSFT) reports quarterly results on October 28 and ranks eighth in Trump's latest stock portfolio, after Trump bought the stock five times in August. Bulls point to Azure growth of 43% last quarter, with management expecting about 45% in the current quarter, and to demand that exceeds available computing capacity. Bears cite rising capital spending that Deutsche Bank says could push free cash flow close to breakeven in fiscal 2027, about two-thirds of spending going to short-lived equipment such as chips, and OpenAI making up about 45% of the commercial backlog in the December quarter. The stock trades at 26.75 times forward earnings, a 27% premium to the sector median of 21.01 but 12% below its own five-year average of 30.47, with a PEG ratio of 1.70 versus a sector median of 1.14. The article concludes that investors pay more than for the average tech stock but less than they usually pay for Microsoft.
- What Is Williams' (WMB) Economic Moat, and Is It Steel or Permits?
Williams (WMB) closed at $71.28 on October 16, with a 0.5% return over 6 months, compared with 10.5% for the Insider Monkey Billionaire Index and 9.3% for the State Street SPDR S&P 500 ETF Trust. The article argues its main advantage is the Transco pipeline, which runs from the Gulf Coast up the eastern seaboard, where several attempts to build new pipe have been abandoned after failing to win approvals. A 39.54% operating margin and 21.50% return on equity are cited as evidence of this advantage, although revenue rose only 7.80% last quarter. Limits noted include debt at 200.37% of equity, rules that also restrict Williams' own growth, and a price of 26.81 times expected next-year earnings. The dividend yields 2.95%.
- Marvell Jumps 6% as GF Securities Says Google Chip Delay Won’t Dent Its Position; Broadcom Rises 3%
Marvell shares rose 6% to $241.27 in afternoon trading after a reported delay in Google's next TPU chip, while Broadcom gained 3%. GF Securities analyst Jeff Pu said the delay does not change Marvell's medium- to long-term position in Google's chip supply chain. Marvell reported Q2 FY2027 revenue of $2.74 billion, up 36.5% YoY, with its Data Center segment at $2.17 billion, or 79% of revenue. Google can acquire up to 7% of Marvell shares under a warrant tied to revenue targets, and management expects its custom business to more than double in fiscal 2028. Q3 revenue guidance is $3.15 billion, plus or minus 5%, with non-GAAP gross margin of 57.5% to 58.5%, and the article notes Marvell still needs to convert its Google programs into reported revenue.
- Is ONEOK (OKE) Cheap at 14 Times Next Year’s Earnings?
ONEOK (NYSE:OKE) closed at $93.31 on October 16 and returned 11.4% over six months, versus 10.5% for the Insider Monkey Billionaire Index. The stock trades at 14.49 times next year's expected earnings and yields 4.59%, and revenue rose 52.80% last quarter as the company grew through acquisitions. The article argues that much of this growth was bought rather than built, with only 13.25% of revenue remaining as operating profit and debt at 143.07% of equity. Because a large part of the business involves buying and reselling liquids rather than earning transport fees, the article views the discount as having a reason behind it. It concludes that investors should watch margins rather than revenue.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.